Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)
Authors:
- Christophe NougierCNChristophe Nougier
- Emmanuelle JeanpierreEJEmmanuelle Jeanpierre
- The Working Group on Biology of Haemorrhagic Disorders (BIMHO, under the aegis of GFHT)TGThe Working Group on Biology of Haemorrhagic Disorders (BIMHO, under the aegis of GFHT)
Open Access
- 15 July 2020
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 105 (6) , 675-681
Abstract
Emicizumab, a bispecific humanised monoclonal antibody restoring to some extent the function of activated FVIII deficient in haemophilia A, represents a major therapeutic advance in the management of haemophilia A patients. No dosage adjustment is required, which leads to a major change for patients used to regular biological monitoring which is particularly burdensome in the case of substitution therapy. In some circumstances, such as before an invasive procedure or in case of bleeding, biological monitoring will be necessary and emicizumab's interference with haemostasis tests, particularly those based on an activated partial thromboplastin times (aPTT), must be known to best interpret the tests and to select the most appropriate methods to guide therapy. The normalisation of aPTT in patients treated with emicizumab is not sufficient to consider haemostasis as normalised. In the event of administration of FVIII to a patient receiving emicizumab, the determination of FVIII should use a chromogenic method using non‐human reagents. Coagulation global tests have been proposed to evaluate the biological response when using bypassing agents in patients treated with emicizumab, but the usefulness must be confirmed. The French group BIMHO presents proposals for biological monitoring of a patient treated with emicizumab according to clinical situations.Keywords
This publication has 19 references indexed in Scilit:
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 studyThe Lancet Haematology, 2019
- Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation AssaysThrombosis and Haemostasis, 2019
- Emicizumab: Review of the literature and critical appraisalHaemophilia, 2018
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agentsJournal of Thrombosis and Haemostasis, 2018
- Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumabHaematologica, 2018
- Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?Blood, 2017
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia ANew England Journal of Medicine, 2016
- A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjectsBlood, 2016